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Abstract
Background: Leishmaniasis is one of the world’s most neglected diseases caused by at least 20 different species of the
protozoan parasite Leishmania. Although new drugs have become recently available, current therapy for leishmaniasis is
still unsatisfactory. A subgroup of serine/threonine protein kinases named as related to A and C protein kinases (RAC), or
protein kinase B (PKB)/AKT, has been identified in several organisms including Trypanosoma cruzi parasites. PKB/AKT plays
a critical role in mammalian cell signaling promoting cell survival and is a major drug target in cancer therapy. However,
the role of protozoan parasitic PKB/AKT remains to be elucidated.
Results: We have found that anti-human AKT antibodies recognized a protein of about 57 kDa in Leishmania spp.
parasites. Anti-human phospho-AKT(Thr308) antibodies identified a protein in extracts from Leishmania spp. that was
upregulated following parasite exposure to stressful conditions, such as nutrient deprivation or heat shock. Incubation of
AKT inhibitor X with Leishmania spp. promastigotes under stressful conditions or with Leishmania-infected macrophages
led to parasite cell death. We have identified and cloned a novel gene from Leishmania donovani named Ld-RAC/AKT-like
gene, encoding a 510-amino acid protein of approximately 57.6 kDa that shows a 26.5% identity with mammalian AKT1.
Ld-RAC/AKT-like protein contains major mammalian PKB/AKT hallmarks, including the typical pleckstrin, protein kinase
and AGC kinase domains. Unlike mammalian AKT that contains key phosphorylation sites at Thr308 and Ser473 in the
activation loop and hydrophobic motif, respectively, Ld-RAC/AKT-like protein has a Thr residue in both motifs. By
domain sequence comparison, we classified AKT proteins from different origins in four major subcategories that
included different parasites.
Conclusions: Our data suggest that Ld-RAC/AKT-like protein represents a Leishmania orthologue of mammalian
AKT involved in parasite stress response and survival, and therefore could become a novel therapeutic and
druggable target in leishmaniasis therapy. In addition, following comparative sequence analyses, we found the
RAC/AKT-like proteins from Leishmania constitute a subgroup by themselves within a general AKT-like protein family.
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Background
Leishmaniasis, caused by at least 20 species of the proto-
zoan parasite Leishmania, is classified in three different
clinical forms, visceral, cutaneous and mucocutaneous
leishmaniasis, which have different immunopathologies
and degrees of morbidity and mortality. Visceral leishman-
iasis, which results in splenomegaly and hepatomegaly, is
caused by L. donovani and L. infantum and is fatal if not
treated. Leishmaniasis is a major health problem in many
parts of the world, affecting 12 million people worldwide,
mainly in developing countries; 350 million people are
considered at-risk of contracting the disease, and some two
million new cases occur yearly [1]. In addition, increasing
immigration, tourism, and military activity in Leishmania
endemic areas have posed a risk, threatening to expand the
disease to nonendemic areas of the world. Major chal-
lenges for antileishmanial chemotherapy include the avail-
ability of few drugs, emergence of drug resistance, toxicity
and lack of cost-effectiveness analysis. The availability of
the complete genome sequence of various species of
Leishmania, including L. major, L. infantum, L. braziliensis,
L. donovani, L. mexicana, L. amazonensis and L. panamen-
sis [2–7] represents an extraordinary resource for the dis-
covery of new antileishmanial targets. The comparison of
the parasite genome with the human genome sequence
facilitates the identification of Leishmania-specific genes
for which drugs could be developed, thereby limiting the
chance for interaction with human homologues. However,
most of the genes found in Leishmania parasites remain
to be characterized, and less than half of annotated genes
have been assigned gene ontology terms.
The serine/threonine kinase protein kinase B (PKB) or
AKT, a member of the AGC family of serine/threonine
kinases, is an important regulator of cell proliferation
and survival in mammalian cells. Data accumulated in
the last decade have established that AKT also plays a
major role in cancer development and progression,
prompting the development of drugs targeting this sur-
vival pathway in cancer therapy [8–11]. The structure of
AKT comprises three conserved domains: an N-terminal
pleckstrin homology (PH) domain, which binds phos-
phoinositides with high affinity; a central catalytic domain;
and a C-terminal regulatory domain [12]. AKT has a wide
range of cellular substrates, and the oncogenicity of AKT
arises from activation of both proliferative and anti-
apoptotic signaling, thus making this kinase an attractive
target for cancer therapy. Activation of mammalian AKT
depends on its recruitment to the membrane through
binding of phosphatidylinositol-3,4,5-trisphosphate (PIP3)
to the PH domain of AKT, and subsequent phosphoryl-
ation at two key residues, Thr308 and Ser473, located at
the catalytic domain and C-terminal regulatory domain,
respectively [13]. The physiological action of AKT kinase
is mediated through the phosphorylation of a wide variety
of downstream substrates [12–15]. One of the major AKT
substrates is glycogen synthase kinase-3 (GSK-3), which
has been identified in Leishmania major and Trypano-
soma brucei and has been suggested as a potential drug
target in trypanosomatids [16–18]. The fast adaptability of
Leishmania parasites to different adverse environments in
their life-cycle, including changes in temperature, pH, and
nutrient availability, suggests these protozoa possess ef-
fective mechanisms to ensure survival in the face of these
challenges. Because glycogen synthase kinase-3 has been
identified in Leishmania parasites and is a substrate of the
cell survival molecule AKT [19], this prompted us to in-
vestigate the putative presence of an AKT homologue in
Leishmania parasites that might represent a potential drug
target. A subgroup of Ser/Thr protein kinases, related to
protein kinases A and C (RAC) and to PKB/AKT, has
been identified in a number of mammalian cells [20],
Drosophila melanogaster [21], Caenorhabditis elegans
[22], Dyctiostelium discoideum [23], Entamoeba histolytica
[24], Giardia intestinalis [25], and Trypanosoma cruzi
[26]. However, no AKT proteins have been so far reported
in Leishmania parasites.
Here, we show that Leishmania spp. express AKT-like
genes. We cloned and sequenced a novel gene, named
Ld-RAC/AKT-like gene, from Leishmania donovani
(MHOM/IN/80Dd8) that encoded a protein closely re-
lated to putative or previously reported RAC serine-
threonine kinases from other Leishmania and Trypano-
soma species, as well as to mammalian AKT. Our data
show that Ld-RAC/AKT-like protein may behave as a
survival molecule in Leishmania parasites, and could
become a novel target for leishmaniasis therapy.
Methods
Cell culture
The Leishmania strains used in this study were: L. pana-
mensis (MHOM/CO/87/UA140), L. infantum (MCAN/
ES/96/BCN150), L. donovani (MHOM/IN/80/Dd8), and
L. braziliensis (MHOM/CO/88/UA301). Leishmania pro-
mastigotes were grown at 26 °C in the RPMI-1640 culture
medium, containing 10% heat-inactivated fetal bovine
serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, and
100 μg/ml streptomycin. Promastigotes in the stationary
growth phase were used for macrophage infection. These
were prepared by incubating a starting inoculum of
1 × 106 parasites/ml for 5–6 days. For the experiments of
nutritional stress, the culture medium was prepared as
above in the absence of FBS. For the thermal shock assays,
parasites were incubated for 3 h at 37 °C in the complete
culture medium as above.
Western blot
1.5 × 107 promastigotes were lysed with 180 μl of
150 mM NaCl, 10 mM HEPES, 1% CHAPS, and 0.1 mM
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sodium orthovanadate, in the presence of protease inhib-
itors (1 mM phenylmethylsulfonyl fluoride, 20 μg/ml
aprotinin, and 20 μg/ml leupeptin). Proteins (40–60 μg)
were subjected to SDS polyacrylamide gel electrophor-
esis under reducing conditions and transferred to PVDF
membranes (Merck Millipore, Billerica, MA, USA).
Membranes were blocked with 5% (w/v) skim milk
powder in 50 mM Tris-HCl (pH 8.0), 150 mM NaCl
and 0.1% (v/v) Tween 20 (TBST) for 90 min at room
temperature, and then incubated for 1 h at room
temperature or overnight at 4 °C with the following pri-
mary antibodies: anti-60 kDa phospho-AKT (pAKT)
(Thr308) and anti-60 kDa pAKT (Ser473) rabbit poly-
clonal antibodies, which recognize the phosphorylated
forms at Thr308 and Ser473 respectively in human
AKT (Cell Signaling Technology, Beverly, MA, USA)
(1:1000 dilution in TBST with 5% BSA), and the anti-
60 kDa AKT rabbit polyclonal antibody (H-136) (1:1000
dilution in TBST with 5% BSA) that recognizes the whole
human protein AKT1/2/3 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Antibody reactivity was monitored
with horseradish peroxidase (HRP)-conjugated anti-rabbit
IgG, using an enhanced chemiluminescence detection kit
ECL-PLUS (GE Healthcare Life Sciences, Piscataway, NJ,
USA). Both Fujifilm super RX autoradiography films
(Tokyo, Japan) and image capture by Odyssey imaging
system (LI-COR Biosciences, Lincoln, NE, USA) were
used to visualize immunoreactive bands. The molecular
weight of the immunoreactive bands was determined
using molecular weight standard markers (Precision
Plus Protein™ standards, BioRad, Hercules, CA, USA).
Flow cytometry determination of apoptosis-like cell death
Leishmania spp. promastigotes (2 × 106) were treated as
indicated, and then parasites were centrifuged (1000 × g,
5 min), and analyzed for apoptosis-like cell death as pre-
viously described after propidium iodide staining [27].
The induction of apoptosis was monitored as the appear-
ance of the sub-G0/G1 phase (hypodiploid cells) in cell
cycle analysis, indicating DNA breakdown [27, 28].
Apoptotic cells were quantified as the percentage of
cells in the sub-G0/G1 region (hypodiploid DNA con-
tent) following cell cycle analysis [27, 28], using a
fluorescence-activated cell sorting (FACS) Calibur flow
cytometer (Becton Dickinson, San Jose, CA, USA). Data
were analyzed with WinMDI 2.8 software (Scripps
Institute, San Diego, CA, USA).
Infection of J774 macrophages with L. panamensis
J774 macrophage-like cells were cultured at the exponen-
tial growth phase (3 × 105 cells/ml) in complete RPMI-
1640 medium (containing 10% FBS, 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin), at 37 °C in
a humidified air/CO2 incubator (95:5, v/v), and then
infected overnight with stationary-phase L. panamensis
promastigotes (1/10 macrophage/promastigote ratio).
Non-internalized promastigotes were washed out (3 PBS
washes). Leishmania-infected macrophages were treated
with 10 μM AKT inhibitor X (10-(4′-(N-diethylamino)
butyl)-2-chlorophenoxazine) (Calbiochem, San Diego,
CA, USA) for 24 h and then stained with Giemsa to
calculate the number of intracellular amastigotes in 100
infected macrophages. In addition, untreated control
and AKT inhibitor X-treated infected macrophages were
pelleted, and the percent of apoptotic macrophages was
analyzed by flow cytometry as indicated above.
mRNA isolation and cDNA synthesis in L. donovani
Total RNA from 1 × 107 L. donovani (MHOM/IN/80/
Dd8) promastigotes was isolated using the RNeasy mini
kit (Qiagen, Hilden, Germany), following the manufac-
turer’s instructions. RNA preparations were carefully
checked by gel electrophoresis and found to be free of
DNA contamination. Total RNA (2 μg), primed with
1 μM oligo-(pdT)15, was reverse-transcribed into cDNA
with 10 units AMV reverse transcriptase (Hoffmann-La
Roche, Basel, Switzerland), according to the manufacturer’s
instructions for 1 h at 42 °C in a final volume of 20 μl. To
evaluate the quality of the generated cDNA, we amplified
the constitutively expressed gene kmp-11 (GenBank/EMBL
accession no. XM_003864757) as previously described
[29]. KMP11 protein is one of the most abundant mole-
cules on the cell surface of Leishmania spp. parasites. The
sense and antisense primers for kmp11 gene cDNA amplifi-
cation were 5′-ATG GCC ACC ACG TAC GAG GAG-3′
and 5′-GGA CGG GTA CTG CGC AGC CTT-3′. PCR
was performed in a GeneAmp PCR system model 9600
(Perkin-Elmer, Norwalk, CT, USA). PCR amplification was
as follows: 1 cycle at 95 °C for 5 min as an initial de-
naturation step, then denaturation at 95 °C for 1 min,
annealing for 1 min at 58 °C, and extension at 72 °C for
1 min (30 cycles). PCR products (236 bp) were electro-
phoresed on 2% agarose gels in 1× TAE buffer (40 mM
Tris-acetate, 1 mM EDTA (pH 8.0)) and visualized by
staining with 0.5 μg/ml ethidium bromide.
Cloning and sequencing of Ld-RAC/AKT-like gene
The cDNA generated as above was submitted to PCR by
using the following sense and antisense primers: 5′-CAC
CAT GAG TGG TTA TTT GAA GGT GCT-3′ and
5′-GGA TCC CTA CTT CGT GGG CTT GTC G-3′,
designed from L. major LmjF.30.0800 (GenBank/EMBL
accession no. XM_001684621). PCR reaction was per-
formed in the presence of 8% DMSO, 1.5 mM MgCl2,
200 μM dNTPs, 2.5 units of GoTaq DNA polymerase, and
1.5 units Pfu DNA polymerase (Promega). PCR was per-
formed in a GeneAmp PCR system model 9600 (Perkin-
Elmer). PCR amplification was as follows: 1 cycle at 95 °C
Varela-M et al. Parasites & Vectors  (2017) 10:458 Page 3 of 10
for 5 min as an initial denaturation step, then denatur-
ation at 95 °C for 30 s, annealing for 50 s at 61 °C, and ex-
tension at 72 °C for 1 min (35 cycles), followed by further
incubation for 15 min at 72 °C (1 cycle). PCR product
(about 1.5 Kb) was electrophoresed on 1% agarose gels in
1× TAE buffer (40 mM Tris-acetate, 1 mM EDTA
(pH 8.0)), and visualized by ethidium bromide staining.
PCR bands were cut, and the amplified DNA was isolated
by using the GFX PCR DNA and Gel Band Purification
kit (GE Healthcare), following the manufacturer’s instruc-
tions. Quantification of the isolated DNA was performed
by using a NanoDrop™ 8000 spectrophotometer (Thermo
Scientific, Waltham, MA, USA). The 1533-bp amplified
product was cloned into the PCR 2.1 TOPO® vector (Invi-
trogen, Carlsbad, CA, USA), following the manufacturer’s
instructions, and using a vector/insert ratio of 1:3. DNA
sequencing was performed by thermal cycle sequencing
using BigDye Terminator v3.1 Cycle Sequencing kit
(Applied Biosystems, Foster City, CA, USA). DNA se-
quencing was performed on both strands from at least
6 independent cDNA clones.
Bioinformatic analysis of protein sequence identity and
similarity
BLASTX, ClustalW2, PROSITE and UniProt databases
were used to determine percentages of identity and
similarity among different proteins and domains. The
UniProt accession numbers used in sequence analysis
were as follows: H. sapiens AKT1 (P31749), H. sapiens
AKT2 (P31751), H. sapiens AKT3 (Q9Y243), M. musculus
(P31748), C. familiaris (E2RJX4), D. melanogaster
(Q8INB9), S. mansoni (G4M056), C. elegans (Q17941),
D. discoideum (P54644), E. histolytica (Q761W9), L. mexi-
cana (E9B0K7), L. braziliensis (A4HI35), L. infantum
(A4I5B1), L. major (Q4Q7M5), L. donovani (Nepal)
(E9BLH8), L. donovani (India) (S6CXR4) (this work), L.
panamensis (A0A0F6QP47), T. cruzi (Q4D6D3), T. bru-
cei (Q584T1), T. vivax (G0TWP8), T. rubrum (F2SV36),
G. intestinalis (C6M0B9), P. yoelii (Q7RSF6), P. falcip-
arum (Q8I4W3).
Protein modeling and inhibitor docking
Because the 3D structure of the Ld-RAC/AKT-like pro-
tein has not been resolved experimentally, we used a
virtual structural model based on its homology with hu-
man AKT1 protein, previously reported in the Protein
Data Bank (PDB). The model was built using the ESy-
Pred3D Web Server 1.0 program [30]. The structure of
the AKT inhibitor X was obtained from ZINC database
[31] in mol2 format. To improve the modeling of the
putative interaction between protein and ligand, we car-
ried out a pairwise alignment between Ld-RAC/AKT-
like protein and human AKT1, mapping the residues of
the active site [32]. Then, the inhibitor was docked into
the Ld-RAC/AKT-like protein using the AutoDock
VINA software [33].
Statistical analysis
The data given are the mean values (± standard deviation,
SD) of the indicated number of experiments. Statistical
significance was determined by a Student’s t-test. Differ-
ences were considered significant at a P-value of < 0.05.
Results
Leishmania parasites express an AKT-immunoreactive
protein that is upregulated under stress conditions
Because AKT signaling plays a critical role in the survival
of mammalian cells, we examined whether anti-human
AKT antibodies recognized a band in Leishmania para-
sites. We found that Western blot analyses with anti-
human AKT polyclonal antibody of L. panamensis
(MHOM/CO/87/UA140) and L. infantum (MCAN/ES/
96/BCN150) promastigotes, previously grown in the pres-
ence or absence of fetal bovine serum (FBS), recognized a
band of about 57 kDa (Fig. 1a). Interestingly, we also
found a 57 kDa band that was immunoreactive against
anti-human pAKT(Thr308) antibodies, highly upregulated
when parasites were incubated in the absence of serum
(Fig. 1a). Similarly, L. panamensis and L. donovani
(MHOM/IN/80/Dd8) promastigotes also expressed the
above AKT-immunoreactive protein (Fig. 1b), as well as
a protein of about 57 kDa by using the anti-human
pAKT(Thr308) antibody when parasites were submitted
to a heat shock at 37 °C (Fig. 1b). However, no band
was detected when anti-human pAKT(Ser473) was
used in parasites grown under stressful conditions.
These data suggest that Leishmania spp. promasti-
gotes express an AKT-like protein that could be recog-
nized by the anti-human AKT antibody, and that this
parasite protein might be phosphorylated in Thr
residues.
AKT inhibition induces apoptosis-like cell death in
Leishmania promastigotes and amastigotes
Next, we analyzed the effect of AKT inhibitor X that
prevents phosphorylation of AKT in mammalian cells
[34]. We found that incubation of 2 × 106Leishmania
promastigotes from different species, including L. pana-
mensis, L. braziliensis, L. infantum and L. donovani, with
AKT inhibitor X did not affect cell viability, provided
serum was present in the culture medium (Fig. 1c), but
AKT inhibitor X induced a potent apoptosis-like cell
death, determined by an increase in the percentage of hy-
podiploid cells (sub-G0/G1 region in cell cycle analysis), as
an indication of DNA breakdown, when parasites were
submitted to stress conditions, such as serum deprivation
or incubation at 37 °C (Fig. 1c, d). Moreover, we also
found that AKT inhibitor X killed J774 macrophage-
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residing L. panamensis amastigotes, as assessed by a
dramatic decrease in the parasitic burden of macro-
phages following Giemsa staining (Fig. 1e), whereas
macrophages were spared as assessed by no DNA
breakdown detection in macrophages analyzed by flow
cytometry (Fig. 1f ).
Cloning and sequence of a gene coding for a protein in
Leishmania donovani (MHOM/IN/80Dd8) that has similarities
to mammalian AKT
Because the above data suggested the presence of an
AKT-like protein in Leishmania parasites, we analyzed
the presence of a putative sequence similar to mammalian
Fig. 1 Anti-AKT and anti-pAKT immunoreactive bands in Leishmania parasites and Leishmania killing by AKT inhibitor X. a L. panamensis (Lp) and
L. infantum (Li) promastigotes were cultured in the presence (+FBS) or absence (−FBS) of FBS, and protein extracts were submitted to Western
blot using anti-human AKT1/2/3 and anti-pAKT(Thr308) polyclonal antibodies. b L. panamensis (Lp) and L. donovani (Ld) promastigotes were cultured at
26 °C or 37 °C, and protein extracts were submitted to Western blot using anti-human AKT1/2/3 and anti-pAKT(Thr308) polyclonal antibodies. The
positions of the immunoreactive bands are indicated by arrows. c Promastigotes of different Leishmania spp. were incubated for 14 h at 26 °C in the
presence (+FBS) or absence (−FBS) of FBS, and without (Control) or with 5 μM AKT inhibitor X. Then, parasites were collected and analyzed for the
induction of apoptosis-like cell death as assessed by the percentage of parasites in the sub-G0/G1 region (hypodiploid cells) by flow cytometry.
d Promastigotes of different Leishmania spp. were incubated at 37 °C for 3 h in the presence or absence (Control) of 5 μM AKT inhibitor X.
Then, parasites were collected and analyzed for the induction of apoptosis-like cell death as assessed by the percentage of parasites in the
sub-G0/G1 region (hypodiploid cells) by flow cytometry. e, f J774 macrophage-like cells infected with L. panamensis were untreated (Control)
or treated with 10 μM AKT inhibitor X for 24 h. Then, the number of intracellular amastigotes was quantified by Giemsa staining (e), and the
percentage of apoptotic macrophages was assessed through the percentage of mammalian cells at the sub-G0/G1 region (hypodiploid cells)
by flow cytometry (f). Data shown are means ± SD or representative of 3 independent experiments. Asterisks indicate statistically significant
differences with respect to control values (**P < 0.01). Western blot experiments shown are representative of 3 performed
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AKT in the already sequenced genome of Nepalese L.
donovani (MHOM/NP/02/BPK282A1). We found that a
gene named as LDBPK_300850 (RAC serine-threonine
kinase, putative) showed a 26.3% identity with the sequence
of human AKT1. By using specific primers designed from
LDBPK_300850, we generated RT-PCR fragments from In-
dian L. donovani (MHOM/IN/80Dd8) mRNA, which were
subsequently cloned and sequenced. Following this strategy,
we isolated and sequenced the LDBPK_300850 homologue
from Indian L. donovani (MHOM/IN/80Dd8). We coined
this gene as Ld-RAC/AKT-like gene, indicating its origin
and the similarity to the previous parasite RAC-like and
mammalian AKT genes. The Ld-RAC/AKT-like cDNA
codes for a protein sequence of 510 amino acids with a de-
duced molecular mass of about 57,612.5 Da and a theoret-
ical isoelectric point (pI) of 6.25. This Ld-RAC/AKT-like
protein contains the typical pleckstrin (PH domain), protein
kinase and AGC kinase domains, which represent the
major hallmarks of mammalian PKB/AKT proteins (Fig. 2).
We found a small number of differences, namely 32
nucleotides (97.8% identity) and 5 amino acid residues
(99% identity), when the corresponding Indian L. dono-
vani (MHOM/IN/80Dd8) and Nepalese L. donovani
(MHOM/NP/02/BPK282A1) homologous sequences were
compared (Fig. 2 and Table 1). The amino acid sequence
of Ld-RAC/AKT-like protein showed a 26.5% identity and
43.2% similarity to the corresponding human AKT1 cod-
ing region (Table 1). Using the ESyPred3D Web Server 1.0
program, we found that the structure of this Ld-RAC/
AKT-like protein is similar to that of human AKT1
(Additional file 1: Figure S1a). Using the Docking Soft-
ware AutoDock VINA, we found that the Ld-RAC/
AKT-like protein probably interacts with AKT inhibitor
X (Additional file 1: Figure S1b). Using the AutoDock
VINA software for binding prediction, the AKT inhibi-
tor X docked into the Ld-RAD/AKT-like protein with
a -7.5 kcal/mol, whereas the interaction between AKT
inhibitor X and human AKT1 was -8.8 kcal/mol, in a 0
to -14 kcal/mol scale, the latter value representing the
highest probability of interaction.
Presence of AKT-like genes in Leishmania and Trypanosoma
parasites
A comparison of the Ld-RAC/AKT-like protein sequence
with those derived from the genome sequences already
available in the databases for Leishmania and Trypano-
soma parasites showed a strong similarity in their respect-
ive primary structures (Leishmania: 92.9–99% identity,
94.5–99.2% similarity; Trypanosoma: 32.5–34.6% identity,
46.3–48.4% similarity) (Table 1). This protein also con-
tained the 12 conserved subdomains of the eukaryotic
protein kinase domain, which were also present in the
predicted homologous sequences of trypanosomatids
(Additional file 2: Figure S2). More extensive compara-
tive analyses of the sequences showing homology with
human AKT in different biological systems, regarding
whole sequences as well as the major PH, kinase and
AGC domains, are shown in Table 2 and Additional file
3: Figure S3, and this comparative analysis prompted us
to classify this large family of genes in four major sub-
categories as shown in Fig. 3. The Leishmania group
shows a longer C-terminal sequence, whereas there is
another subcategory that lacks the PH domain (Fig. 3).
Differential presence of Thr and Ser amino acid residues
at the phosphorylation sites in mammalian and
Leishmania AKT-like genes
The full activation of mammalian AKT is accomplished
by its phosphorylation at two key residues, Thr308 and
Ser473 [13]. The Thr308 site is located in the activation
loop within the catalytic domain, while Ser473 is located
in the C-terminal hydrophobic motif of mammalian
AKT. Interestingly, AKT-like proteins from Leishmania
spp. have the Thr residue in the activation loop, but
showed another Thr residue instead of the mammalian
Ser residue at the hydrophobic motif (Fig. 4). Thus, the
Fig. 2 Amino acid sequence of Ld-RAC/AKT-like protein from L. donovani. The nucleotide and predicted amino acid sequences of Ld-RAC/AKT-like
gene are available from GenBank/EMBL database under accession number HF548848. The PH, kinase and AGC kinase domains of the Ld-RAC/AKT-like
protein are underlined in green, blue and red, respectively. This primary sequence shows five differences in amino acids (underlined in black)
when compared to a previously homologous sequence from another L. donovani strain (MHOM/NP/02/BPK282A1) (Genbank/EMBL accession
number: XM_003862750)
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typical FPQFSY hydrophobic motif of mammalian AKT
becomes LAGYTY in Leishmania parasites (Fig. 4). The
absence of this Ser residue might explain the lack of de-
tection of a protein band in Leishmania spp. extracts
when an anti-human pAKT(Ser473) antibody was used,
as stated above. Likewise, the corresponding AKT-like
sequences from T. brucei and T. vivax also lacked the
Ser residue at the hydrophobic motif (Fig. 4). However,
the AKT-like amino acid sequence from T. cruzi con-
tained the Ser residue at the hydrophobic motif (IACFSF)
(Fig. 4), and therefore it was the only AKT-like sequence
of the Trypanosomatidae family that showed homology
with mammalian AKT regarding these critical phosphor-
ylation sites.
Discussion
Our data revealed that Leishmania donovani parasites
express the Ld-RAC/AKT-like gene encoding a protein
of 57.6 kDa that shows a significant identity (26.5%) and
similarity (43.2%) with mammalian AKT1. Antibodies
against human AKT recognize a protein in Leishmania
spp. of about 57 kDa that is suggested to be phosphorylated
under stressful conditions, such as nutrient deprivation and
heat shock. Comparison of the Ld-RAC/AKT-like protein
amino acid sequence with those of known eukaryotic Ser/
Thr protein kinases indicates that the newly described L.
donovani protein belongs to the RAC or PKB/AKT sub-
group of proteins. Because PKB/AKT has a major prosurvi-
val role in mammalian cells [10, 20], our data suggest that
the Ld-RAC/AKT-like protein could represent part of a
PKB/AKT signaling pathway present in trypanosomatids,
and thereby might play a role in Leishmania survival during
its complex life-cycle. On these grounds, inhibition of this
AKT-like signaling pathway in Leishmania could be a novel
approach to the search of anti-Leishmania drugs. The in-
duction of apoptosis-like cell death in Leishmania spp. by
the AKT inhibitor X, when parasites are submitted to stress
conditions, further supports the involvement of an AKT
signaling pathway in Leishmania parasite survival. It is
tempting to suggest that parasites growing in nutrient-
deficient medium or at high temperature might defend
themselves by triggering phosphorylation of the Ld-RAC/
AKT-like protein, thus prompting a survival response to
detrimental conditions. Our data suggest that blocking this
response by an AKT inhibitor might facilitate Leishmania
cell death. Ld-RAC/AKT-like protein and human AKT1
show a 26.5% identity, suggesting the existence of differ-
ences that might be exploited to identify drugs inhibiting
selectively to the Leishmania AKT homologue. In this re-
gard, pleckstrin homology (PH) and AGC domains, which
are involved in the membrane localization and function of
Table 1 Comparison of Ld-RAC/AKT-like gene with trypanosomatid
and human homologues. Identity and similarity percentages of the
full cDNA and protein sequences are shown as compared to the
herein reported Ld-RAC/AKT-like gene from L. donovani (MHOM/
IN/80/Dd8)
Species cDNA % identity Protein % identity Protein %
similarity
L. donovani (Nepal) 97.8 98.0 99.2
L. braziliensis 89.6 92.9 94.5
L. infantum 97.7 98.8 99.2
L. major 98.0 98.8 98.8
L. mexicana 96.0 96.7 97.6
L. panamensis 90.1 93.9 96.6
T. cruzi 45.6 32.5 46.3
T. vivax 41.8 32.9 48.1
T. brucei 42.0 34.6 48.4
Human AKT1 43.9 26.5 43.2
Human AKT2 42.1 26.1 41.5
Human AKT3 43.8 25.4 40.7
Table 2 Comparison of human AKT1 with RAC/AKT kinases from
different origins. Identity and similarity percentages of the full
protein as well as percentages of similarity in the distinct domains
are shown. Sequence alignment was performed using the
Needleman-Wunsch algorithm
Species Identity Similarity
Full
Protein
Full
Protein
PH
Domain
Kinase
Domain
AGC
Domain
H. sapiens 100 100 100 100 100
M. musculus 98.3 99.0 99.0 99.6 97.2
C. familiaris 96.9 98.3 100 99.2 93.1
D. melanogaster 48.6 60.5 71.3 88.4 62.3
S. mansoni 47.9 58.5 74.0 81.5 52.6
C. elegans 51.8 65.8 72.1 83.0 60.3
D. discoideum 41.5 58.5 43.9 72.7 46.7
E. histolytica 37.5 56.0 45.8 70.3 41.8
L. mexicana 26.3 43.0 28.9 61.7 36.8
L. braziliensis 26.8 42.1 28.7 61.7 21.7
L. infantum 26.3 42.8 29.8 61.7 29.6
L. major 26.0 41.9 26.0 61.7 29.6
L. donovani (India) 26.5 43.2 29.8 61.7 29.6
L. donovani (Nepal) 26.3 42.8 29.8 61.7 29.6
L. panamensis 35.0 55.0 43.0 63.0 19.3
T. cruzi 33.0 52.6 42.0 64.6 37.2
T. brucei 32.7 50.9 36.8 63.6 41.0
T. vivax 34.7 54.3 42.3 64.8 45.2
T. rubrum 25.9 38.2 3.0 69.3 43.4
G. intestinalis 27.2 41.1 14.9 58.0 38.4
P. yoelii 23.2 35.0 3.9 71.8 50.0
P. falciparum 23.1 34.8 6.7 74.5 45.3
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AKT proteins [35–37], could represent interesting targets
for the search of specific antileishmanial drugs, as the per-
centage of similarity between the amino acid sequences of
Leishmania parasites with respect to that of human cells
ranges 26–43% for the PH domain and from 19.3 to 36.8%
for the AGC domain in the distinct Leishmania species
(Table 2). Thus, the search for specific amino acid
sequences as drug targets in these domains of the
RAC/AKT-like proteins in Leishmania parasites could
minimize putative side effects by their absence in the
cognate human counterparts.
Following primary sequence comparison, we postulate
the evolutionary conservation of the PKB/AKT signaling
pathway in different parasites. Trypanosomatidae parasite
Fig. 3 Classification of RAC/AKT-like proteins in four major subcategories. This scheme depicts the alignment of the different amino acid sequences
corresponding to RAC/AKT-like proteins in four major subcategories, based on the presence of the three typical PH (green), kinase (blue) and AGC
(red) domains of AKT proteins. The last group does not contain the PH domain, but it is included here because of its homology regarding the other
two domains. The Leishmania group shows a longer C-terminal sequence
Fig. 4 Differences in the amino acids involved in AKT phosphorylation in the RAC/AKT-like protein family. The alignments of the distinct VIb
catalytic loop, VIII activation loop and hydrophobic motif, where D is important for phosphotransference, T for AKT phosphoactivation, and S for
AKT activity potentiation, respectively, are shown, with the above amino acid residues highlighted in bold. RAC/AKT-like proteins from Leishmania
spp. have T instead of S in the hydrophobic motif. Likewise, proteins derived from T. brucei and T. vivax have T instead of S, whereas T. cruzi
shows the same S residue as the human AKT1
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homologues contain the hallmark traits of PKB/AKT pro-
teins, such as the presence of pleckstrin, protein kinase
and AGC kinase domains. Here we classify the RAC/
AKT-like family of proteins in four major subcategories
that include the parasitic homologues, Leishmania par-
asites forming a major group on their own (Fig. 3).
Only one subcategory, comprised of P. falciparum, P.
yoelii, T. rubrum and G. intestinalis (a.k.a. Giardia lam-
blia), lacks the pleckstrin-homologous domain. Inter-
estingly, while mammalian AKT is activated through
phosphorylation at both Thr308 and Ser473 key resi-
dues in the activation loop and hydrophobic motif
[13], the Leishmania AKT homologue lacks the corre-
sponding Ser residue and shows Thr in both motifs. It
is worth to note that, unlike Leishmania parasites, T.
cruzi AKT-like homologue, but not T. brucei and T.
vivax homologues, contains both Thr and Ser residues
in its sequence, similarly to what occurs in human
PKB/AKT (Fig. 4).
Activation of host cell phosphatidylinositol 3-kinase
and PKB/AKT activities by T. cruzi has been shown to
be an early invasion signal required for trypomastigote
internalization [38]. Thus, PKB/AKT signaling is sug-
gested to be associated with parasite invasion and sur-
vival, and therefore it might represent a novel target for
the treatment of leishmaniasis. Taken together, the iden-
tification of Ld-RAC/AKT-like protein may lead to the
eventual design of approaches and drugs targeting Leish-
mania parasites.
Conclusions
In this study, a new gene, Ld-RAC/AKT-like gene, was
identified in Leishmania donovani, which showed a signifi-
cant similarity with mammalian PKB/AKT. Anti-human
AKT antibodies recognized a band of about 57 kDa in
Leishmania parasites, which was suggested to be phos-
phorylated under parasite exposure to stressful conditions,
such as nutrient deprivation or heat shock. Incubation of
AKT inhibitor X with Leishmania spp. promastigotes
under stressful conditions or with Leishmania-infected
macrophages led to parasite cell death. Following extensive
comparative protein sequence analyses in different bio-
logical systems, regarding whole sequences, as well as the
major PH, kinase and AGC domains, RAC/AKT proteins
could be classified into four major groups, with those de-
rived from Leishmania spp. constituting a subgroup with
unique sequence features within the general forming AKT-
like protein family. Taken together, these data suggest that
the new Ld-RAC/AKT-like gene herein cloned represents a
Leishmania orthologue of mammalian AKT involved in
parasite stress response and survival, and therefore could
become a novel therapeutic and druggable target in
leishmaniasis therapy.
Additional files
Additional file 1: Figure S1. Prediction of 3D structures of human
AKT1 and Ld-RAC/AKT-like protein, and interaction with AKT inhibitor X.
a Human AKT1 and Ld-RAC/AKT-like proteins were modeled using the
ESyPred3D Web Server 1.0 program. The α-helical and β-strand domains
are colored magenta and yellow, respectively, while turns are colored
violet. b Different views of the predicted interaction between Ld-RAC/
AKT-like protein and AKT inhibitor X using the AutoDock VINA software.
(upper left) The whole protein surface is shown and the black arrow
indicates the location of the inhibitor X. (upper right) The cavity of the
ATP binding pocket at higher magnification is displayed, showing the
interaction with AKT inhibitor X. The images at the lower panels show
the inhibitor X within the ATP binding pocket in vertical and horizontal
position interacting with the protein (TIFF 9524 kb)
Additional file 2: Figure S2. Alignment of the catalytic domains of the
distinct RAC/AKT-like proteins present in Leishmania spp. and Trypanosoma
spp. parasites. Multiple sequence alignment was performed using the
ClustalW program. The accession numbers of the UniProt sequences analyzed
here are as follows: L. braziliensis (A4HI35), L. panamensis (A0A0F6QP47), L.
mexicana (E9B0K7), L. major (Q4Q7M5), L. donovani (India) (S6CXR4) (this work),
L. donovani (Nepal) (E9BLH8), L. infantum (A4I5B1), T. cruzi (Q4D6D3), T. brucei
(Q584T1), T. vivax (G0TWP8). The distinct conserved subdomains of the
catalytic domain are indicated by Roman numerals (I-XI). Asterisks indicate
identity and small dots represent similarity (DOCX 18 kb)
Additional file 3: Figure S3. Analysis of RAC/AKT proteins from different
origins. Multiple sequence alignment was performed using the Clustal O
(1.2.4) program. Asterisks indicate identity and small dots represent similarity
(DOC 50 kb)
Abbreviations
FACS: fluorescence-activated cell sorting; FBS: fetal bovine serum;
GSK-3: glycogen synthase kinase-3; PBS: phosphate-buffered saline;
PDB: Protein Data Bank; PH: pleckstrin homology domain; pI: isoelectric point;
PKB: protein kinase B; RAC: related to A and C protein kinases
Acknowledgments
The authors wish to thank Dr. Iván D. Vélez (PECET, Medellín, Colombia) and
Dr. Antonio Jiménez-Ruiz (Universidad de Alcalá, Alcalá de Henares, Madrid,
Spain) for kindly providing the Leishmania species used in this work.
Availability of data and material
The data supporting the conclusions of this article are included within the
article. The nucleotide and predicted amino acid sequences of Ld-RAC/AKT-like
gene are available from GenBank/EMBL database under the accession number
HF548848.
Funding
This work was financially supported by the Ministerio de Economía y
Competitividad of Spain (SAF2011–30518 and SAF2014–59716-R), Instituto de
Salud Carlos III (RD12/0036/0065 from Red Temática de Investigación
Cooperativa en Cáncer - RTICC, co-funded by the EU’s European Regional
Development Fund - FEDER; RD16/0027/0018 from Red de Investigación
Colaborativa en Enfermedades Tropicales - RICET), IBSAL (IBY15/00003), and
COLCIENCIAS-Colombia (project number: 111556934507).
Authors’ contributions
FM and REVM conceived and designed the experiments. REVM performed
the cloning and biochemical experiments, and protein sequence analyses.
RO and CEM carried out protein modeling studies. REVM, RO and CEM
performed inhibitor docking studies. REVM, AM and FM analyzed the data.
REVM and FM prepared the figures and Tables. FM wrote the paper. All
authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Varela-M et al. Parasites & Vectors  (2017) 10:458 Page 9 of 10
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación
del Cáncer, Consejo Superior de Investigaciones Científicas
(CSIC)-Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca,
Spain. 2Facultad de Ciencias Básicas, Universidad Santiago de Cali, Campus
Pampalinda, Santiago de Cali, Colombia. 3Programa de Estudio y Control de
Enfermedades Tropicales (PECET), Universidad de Antioquia, Medellín,
Colombia. 4Laboratorio de Inmunología Parasitaria y Molecular, IBSAL-CIETUS,
Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de
Unamuno, Salamanca, Spain. 5Laboratory of Cell Death and Cancer Therapy,
Department of Cellular and Molecular Medicine, Centro de Investigaciones
Biológicas, CSIC, C/ Ramiro de Maeztu 9, E-28040 Madrid, Spain.
Received: 15 March 2017 Accepted: 13 September 2017
References
1. WHO. Control of the leishmaniases. World Health Organ Tech Rep Ser.
2010;949:1–186.
2. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, Berriman M, et al.
The genome of the kinetoplastid parasite, Leishmania major. Science.
2005;309:436–42.
3. Peacock CS, Seeger K, Harris D, Murphy L, Ruiz JC, Quail MA, et al.
Comparative genomic analysis of three Leishmania species that cause
diverse human disease. Nat Genet. 2007;39:839–47.
4. Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, et
al. Whole genome sequencing of multiple Leishmania donovani clinical
isolates provides insights into population structure and mechanisms of drug
resistance. Genome Res. 2011;21:2143–56.
5. Rogers MB, Hilley JD, Dickens NJ, Wilkes J, Bates PA, Depledge DP, et al.
Chromosome and gene copy number variation allow major structural change
between species and strains of Leishmania. Genome Res. 2011;21:2129–42.
6. Real F, Vidal RO, Carazzolle MF, Mondego JM, Costa GG, Herai RH, et al. The
genome sequence of Leishmania (Leishmania) amazonensis: functional
annotation and extended analysis of gene models. DNA Res. 2013;20:567–81.
7. Llanes A, Restrepo CM, Del Vecchio G, Anguizola FJ, Lleonart R. The
genome of Leishmania panamensis: insights into genomics of the L.
(Viannia) subgenus. Sci Rep. 2015;5:8550.
8. LoPiccolo J, Granville CA, Gills JJ, Dennis PA. Targeting Akt in cancer
therapy. Anti-Cancer Drugs. 2007;18:861–74.
9. Falasca M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy
to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des. 2010;16:1410–6.
10. Gdowski A, Panchoo M, Treuren TV, Basu A. Emerging therapeutics for
targeting Akt in cancer. Front Biosci (Landmark Ed). 2016;21:757–68.
11. Asati V, Mahapatra DK, Bharti SK. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK
signaling pathways inhibitors as anticancer agents: structural and
pharmacological perspectives. Eur J Med Chem. 2016;109:314–41.
12. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt
to follow. Trends Biochem Sci. 2001;26:657–64.
13. Franke TF. PI3K/Akt: getting it right matters. Oncogene. 2008;27:6473–88.
14. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/
Akt/mTOR pathway: effective combinations and clinical considerations. Drug
Resist Updat. 2008;11:32–50.
15. Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal.
2011;23:1515–27.
16. Ojo KK, Gillespie JR, Riechers AJ, Napuli AJ, Verlinde CL, Buckner FS, et al.
Glycogen synthase kinase 3 is a potential drug target for African
trypanosomiasis therapy. Antimicrob Agents Chemother. 2008;52:3710–7.
17. Xingi E, Smirlis D, Myrianthopoulos V, Magiatis P, Grant KM, Meijer L, et al.
6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial
glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle
progression and induces apoptosis-like death: exploitation of GSK-3 for
treating leishmaniasis. Int J Parasitol. 2009;39:1289–303.
18. Ojo KK, Arakaki TL, Napuli AJ, Inampudi KK, Keyloun KR, Zhang L, et al.
Structure determination of glycogen synthase kinase-3 from Leishmania
major and comparative inhibitor structure-activity relationships with
Trypanosoma brucei GSK-3. Mol Biochem Parasitol. 2011;176:98–108.
19. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell
cycle progression. Cell Cycle. 2003;2:339–45.
20. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and
cell survival. J Cell Mol Med. 2005;9:59–71.
21. Scanga SE, Ruel L, Binari RC, Snow B, Stambolic V, Bouchard D, et al. The
conserved PI3'K/PTEN/Akt signaling pathway regulates both cell size and
survival in Drosophila. Oncogene. 2000;19:3971–7.
22. Paradis S, Ruvkun G. Caenorhabditis elegans Akt/PKB transduces insulin
receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription
factor. Genes Dev. 1998;12:2488–98.
23. Meili R, Ellsworth C, Firtel RA. A novel Akt/PKB-related kinase is essential for
morphogenesis in Dictyostelium. Curr Biol. 2000;10:708–17.
24. Que X, Reed SL. Expression and characterization of a rac family protein
kinase of Entamoeba histolytica. Mol Biochem Parasitol. 1994;66:111–8.
25. Kim KT, Mok MT, Edwards MR. Protein kinase B from Giardia intestinalis.
Biochem Biophys Res Commun. 2005;334:333–41.
26. Pascuccelli V, Labriola C, Tellez-Inon MT, Parodi AJ. Molecular and
biochemical characterization of a protein kinase B from Trypanosoma cruzi.
Mol Biochem Parasitol. 1999;102:21–33.
27. Gajate C, Santos-Beneit AM, Macho A, Lazaro M, Hernandez-De Rojas A,
Modolell M, et al. Involvement of mitochondria and caspase-3 in ET-18-
OCH3-induced apoptosis of human leukemic cells. Int J Cancer. 2000;86:
208–18.
28. Gajate C, Barasoain I, Andreu JM, Mollinedo F. Induction of apoptosis in
leukemic cells by the reversible microtubule-disrupting agent 2-methoxy-5-
(2′,3′,4′-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one: protection by Bcl-2
and Bcl-XL and cell cycle arrest. Cancer Res. 2000;60:2651–9.
29. Ramirez JR, Berberich C, Jaramillo A, Alonso C, Velez IV. Molecular and
antigenic characterization of the Leishmania (Viannia) panamensis kinetoplastid
membrane protein-11. Mem Inst Oswaldo Cruz. 1998;93:247–54.
30. Lambert C, Leonard N, De Bolle X, Depiereux E. ESyPred3D: prediction of
proteins 3D structures. Bioinformatics. 2002;18:1250–6.
31. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool
to discover chemistry for biology. J Chem Inf Model. 2012;52:1757–68.
32. Blake JD, Cohen FE. Pairwise sequence alignment below the twilight zone. J
Mol Biol. 2001;307:721–35.
33. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of
docking with a new scoring function, efficient optimization, and multithreading.
J Comput Chem. 2010;31:455–61.
34. Thimmaiah KN, Easton JB, Germain GS, Morton CL, Kamath S, Buolamwini
JK, Houghton PJ. Identification of N10-substituted phenoxazines as potent
and specific inhibitors of Akt signaling. J Biol Chem. 2005;280:31924–35.
35. Scheffzek K, Welti S. Pleckstrin homology (PH) like domains - versatile
modules in protein-protein interaction platforms. FEBS Lett. 2012;586:2662–73.
36. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases.
Nat Rev Mol Cell Biol. 2010;11:9–22.
37. Arencibia JM, Pastor-Flores D, Bauer AF, Schulze JO, Biondi RM. AGC protein
kinases: from structural mechanism of regulation to allosteric drug development
for the treatment of human diseases. Biochim Biophys Acta. 1834;2013:1302–21.
38. Wilkowsky SE, Barbieri MA, Stahl P, Isola EL. Trypanosoma cruzi:
phosphatidylinositol 3-kinase and protein kinase B activation is associated
with parasite invasion. Exp Cell Res. 2001;264:211–8.
Varela-M et al. Parasites & Vectors  (2017) 10:458 Page 10 of 10
